InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,624.54
(
-0.03%
)
US TECH 100
18,836.40
(
-0.93%
)
Dow Jones
41,664.23
(
0.65%
)
Brent Oil
72.55
(
1.63%
)
Bitcoin
58,313.44
(
-1.46%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: investorgold2002 post# 121523

Monday, 06/13/2011 12:53:21 AM

Monday, June 13, 2011 12:53:21 AM

Post# of 253125

MNTA—I am not sure I agree with your characterization of "legacy business" that Wheeler was talking about.

I’m very, very sure that legacy business in this context used on the GS webcast refers to prospective partners’ traditional branded biologics, not to their biosimilars.

If you don’t want to take my word for it, call MNTA and ask.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up